ENGLEWOOD CLIFFS, N.J.
Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.
The abstract highlights the radio-mitigative potential of its lead investigational compound, EC-18 in gastrointestinal acute radiation syndrome.
The details of the presentation are as follows:
Presentation Title: “Mitigation of gastrointestinal acute radiation syndrome by 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol via inhibition of necroptosis in mice”
Presenters: Drs. Yong Jae Kim and Jinseon Jeong
Date/Time: Wednesday, October 19, 17:15-18:30 HAST (11:15-12:30 ET)
Session: Radioprotection/Biodosimetry
“We are excited to present our results at the 2022 RRS conference, that support EC-18’s unique mechanism of action to potentially treat gastrointestinal acute radiation syndrome,” said Ki Young Sohn, CEO & Chairman of Enzychem Lifesciences. Based on these results, EC-18 has shown an effect on histopathological improvement of intestinal tissues, leading to functional restoration of the gastrointestinal tract.”
About Enzychem Lifesciences
Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis. Enzychem is headquartered in South Korea, with an office in the United States. For more information, please visit www.enzychem.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005090/en/
CONTACT
Investors / Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
Sanghyun Lee
Enzychem Lifesciences
noah.lee@enzychem.com
